ATTENTION LONG-TERM ALDEYRA THERAPEUTICS, INC. (NA
Post# of 46
(Total Views: 106)
Posted On: 04/11/2024 12:29:49 PM
ATTENTION LONG-TERM ALDEYRA THERAPEUTICS, INC. (NASDAQ: ALDX) INVESTORS
Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of Aldeyra have breached their fiduciary duties owed to the company.
Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to January 7, 2021 should click here: https://grabarlaw.com/the-latest/aldeyra-sahr...stigation/. You can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to you whatsoever.
Why: A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, it is alleged that the Company made false and misleading statements about or failed to disclose: (i) the ADX-2191 new drug application (“NDA”) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, Aldeyra had overstated ADX-2191's clinical and/or commercial prospects; and (iv) as a result, Aldeyra’s public statements were materially false and misleading at all relevant times.
If you have continuously held Aldeyra shares since prior to January 7, 2021, you are encouraged to visit https://grabarlaw.com/the-latest/aldeyra-sahr...stigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com or Mia R. Heller at mheller@grabarlaw.com, or call 267-507-6085.
$ALDX #Aldeyra
Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of Aldeyra have breached their fiduciary duties owed to the company.
Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to January 7, 2021 should click here: https://grabarlaw.com/the-latest/aldeyra-sahr...stigation/. You can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to you whatsoever.
Why: A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, it is alleged that the Company made false and misleading statements about or failed to disclose: (i) the ADX-2191 new drug application (“NDA”) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, Aldeyra had overstated ADX-2191's clinical and/or commercial prospects; and (iv) as a result, Aldeyra’s public statements were materially false and misleading at all relevant times.
If you have continuously held Aldeyra shares since prior to January 7, 2021, you are encouraged to visit https://grabarlaw.com/the-latest/aldeyra-sahr...stigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com or Mia R. Heller at mheller@grabarlaw.com, or call 267-507-6085.
$ALDX #Aldeyra
(0)
(0)